Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 9/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 9/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040115 | 0.89 | UBE2M (0.45) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL4145544 | 0.89 | UBE2M (0.45) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL10313908 | 0.89 | UBE2M (0.42) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL4135802 | 0.88 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL12079774 | 0.87 | UBE2M (0.43) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL5040367 | 0.87 | UBE2M (0.47) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL4128959 | 0.85 | UBE2M (0.44) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL4136379 | 0.85 | UBE2M (0.44) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL4131969 | 0.85 | UBE2M (0.44) | UBE2MDCUN1D1LMNAKCNH2THRB | |
| SCHEMBL2799801 | 0.85 | UBE2M (0.45) | UBE2MDCUN1D1LMNATHRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | UBE2M 3579/4885DCUN1D1 733/4885LMNA 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.